Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
Status:
Completed
Trial end date:
2019-11-26
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well erlotinib hydrochloride works in Treating participants
with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in
chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading.